Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,474 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,543 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06877676 | Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Sep 25, 2026 | clinicaltrials |
| NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | approved for marketing | — | — | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 1, 2026 |
| clinicaltrials |
| NCT05592743 | Vorasidenib Expanded Access Program | approved for marketing | — | — | ServierINDUSTRY | 0 | Jul 24, 2026 | clinicaltrials |
| NCT04507503 | Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements | approved for marketing | — | — | Taiho Oncology, Inc.INDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05757973 | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Dec 9, 2025 | clinicaltrials |
| NCT06132191 | Expanded Access Use of Cemiplimab in Patients With Solid Tumors | approved for marketing | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Nov 20, 2025 | clinicaltrials |
| NCT05164250 | Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM) | approved for marketing | — | — | Regeneron PharmaceuticalsINDUSTRY | 0 | Nov 10, 2025 | clinicaltrials |
| NCT04617002 | Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04220203 | Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer | approved for marketing | — | — | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 0 | Jun 26, 2025 | clinicaltrials |
| NCT05463939 | Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 15, 2025 | clinicaltrials |
| NCT04599712 | Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT05401214 | Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination) | approved for marketing | — | — | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 13, 2025 | clinicaltrials |
| NCT04100694 | Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor | approved for marketing | — | — | Merus B.V.INDUSTRY | 0 | May 20, 2025 | clinicaltrials |
| NCT06064500 | Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer | approved for marketing | — | — | AmgenINDUSTRY | 4 | Mar 10, 2025 | clinicaltrials |
| NCT03133988 | Margetuximab Expanded Access Program | approved for marketing | — | — | TerSera Therapeutics LLCINDUSTRY | 0 | Feb 14, 2025 | clinicaltrials |
| NCT01833039 | An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma | approved for marketing | — | — | Janssen Biotech, Inc.INDUSTRY | 3 | Feb 3, 2025 | clinicaltrials |
| NCT03906331 | Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 13 | Jan 17, 2025 | clinicaltrials |
| NCT02065765 | International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 5 | Jan 9, 2025 | clinicaltrials |
| NCT02307812 | Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Jan 9, 2025 | clinicaltrials |
| NCT04809584 | 18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer | approved for marketing | — | — | Stanford UniversityOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT05172700 | Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | approved for marketing | — | — | Loxo Oncology, Inc.INDUSTRY | 0 | Dec 18, 2024 | clinicaltrials |
| NCT03763604 | Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 14 | Dec 16, 2024 | clinicaltrials |
| NCT03994627 | Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma | approved for marketing | — | — | Eli Lilly and CompanyINDUSTRY | 11 | Dec 16, 2024 | clinicaltrials |
| NCT05760586 | Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma | approved for marketing | — | — | Day One Biopharmaceuticals, Inc.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT00906984 | TheraSphere® for Treatment of Unresectable Hepatocellular Carcinoma(TheraSphere) | approved for marketing | — | — | University of California, IrvineOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05733650 | Expanded Access Program for Epcoritamab | approved for marketing | — | — | GenmabINDUSTRY | 0 | May 25, 2023 | clinicaltrials |
| NCT05345678 | Himalaya Early Access Program | approved for marketing | — | — | AstraZenecaINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04535557 | An Expanded Access Protocol for Mobocertinib in Refractory Non-small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Exon20 Insertion Mutations | approved for marketing | — | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Sep 30, 2022 | clinicaltrials |
| NCT04395508 | An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic | approved for marketing | — | — | Genentech, Inc.INDUSTRY | 1 | Jul 5, 2022 | clinicaltrials |
| NCT03817515 | Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation | approved for marketing | — | — | Aadi Bioscience, Inc.INDUSTRY | 0 | Mar 16, 2022 | clinicaltrials |
| NCT04452136 | Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer | approved for marketing | — | — | Jeanne LinkOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT04829422 | Early Access Program of Lazertinib in Republic of Korea | approved for marketing | — | — | Yuhan CorporationINDUSTRY | 0 | Mar 3, 2022 | clinicaltrials |
| NCT04162756 | Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies(ZUMA-18) | approved for marketing | — | — | Kite, A Gilead CompanyINDUSTRY | 1 | Oct 14, 2021 | clinicaltrials |
| NCT04320693 | Expanded Access for IMMU-132 | approved for marketing | — | — | Gilead SciencesINDUSTRY | 0 | Aug 19, 2021 | clinicaltrials |
| NCT04204928 | Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Aug 13, 2021 | clinicaltrials |
| NCT04943952 | JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Aug 3, 2021 | clinicaltrials |
| NCT04348682 | Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging | approved for marketing | — | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT03070093 | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | approved for marketing | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Apr 20, 2021 | clinicaltrials |
| NCT01076517 | A Humanitarian Device Exemption Treatment Protocol of TheraSphere For Treatment of Unresectable Hepatocellular Carcinoma | approved for marketing | — | — | Stanford UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04504513 | Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer | approved for marketing | — | — | G1 Therapeutics, Inc.INDUSTRY | 0 | Mar 19, 2021 | clinicaltrials |
| NCT04377152 | Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT04334837 | Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) | approved for marketing | — | — | Curium US LLCINDUSTRY | 0 | Oct 9, 2020 | clinicaltrials |
| NCT03723135 | Expanded Access for CC-486 | approved for marketing | — | — | CelgeneINDUSTRY | 1 | Sep 18, 2020 | clinicaltrials |
| NCT04300803 | Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL | approved for marketing | — | — | MorphoSys AGINDUSTRY | 0 | Aug 28, 2020 | clinicaltrials |
| NCT03862885 | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | approved for marketing | — | — | Blueprint Medicines CorporationINDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT01480128 | Multicenter Single-port Colectomy RCT(SIMPLE) | approved for marketing | — | — | The Catholic University of KoreaOTHER | 1 | Jun 19, 2020 | clinicaltrials |
| NCT04291937 | A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA | approved for marketing | — | — | Jazz PharmaceuticalsINDUSTRY | 0 | Jun 19, 2020 | clinicaltrials |
| NCT04148092 | Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST | approved for marketing | — | — | Deciphera Pharmaceuticals, LLCINDUSTRY | 0 | May 29, 2020 | clinicaltrials |
| NCT01377532 | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma | approved for marketing | — | — | University of California, San FranciscoOTHER | 1 | May 6, 2020 | clinicaltrials |
| NCT01632826 | Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma(PEXIUS) | approved for marketing | — | — | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials